NCT00644917 is a Phase 1 clinical trial of Xenaderm in Healthy, sponsored by Healthpoint.

Who is sponsoring NCT00644917?

NCT00644917 is sponsored by Healthpoint.

What drugs are being tested in NCT00644917?

Interventions in NCT00644917: Xenaderm, Placebo.

Is NCT00644917 still recruiting?

NCT00644917 is currently completed. Last updated 11 December 2013.

Are results published for NCT00644917?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2013-12-11 · How we verify

NCT00644917

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Evaluation of the Phototoxic Potential of Xenaderm Ointment

Completed Phase 1 Results posted Last updated 11 December 2013

What this trial tests

Phase 1 trial testing Xenaderm in Healthy in 38 participants. Completed in 1 February 2008.

Timeline

1 February 2008

Primary endpoint
1 February 2008

1 February 2008

Quick facts

Lead sponsor	Healthpoint
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	quadruple
Enrollment	38
Start date	1 February 2008
Primary completion	1 February 2008
Estimated completion	1 February 2008

Drugs / interventions tested

Xenaderm — full drug profile →
Placebo

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Healthpoint — full company profile →

Who can join

18 and older, any sex, with Healthy. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Skin Reaction Score
Time frame: 48 hours
Scores for phototoxic skin irritation were used to evaluate safety. In this study, irritation was graded using a scale that ranged from 0 (no reaction) to 7 (large vesiculo-bullous reaction) in whole units.

Sponsor's own description

The product is being tested to see if exposure to light causes toxic reactions on the skin.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00644917 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Healthpoint
Last refreshed: 11 December 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00644917.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing